Anthos receives FDA’s Fast Track designation for a drug candidate targeting patients with AFib
This is the second Fast Track designation Anthos has received for abelacimab in less than two months. The therapeutic is also the first Factor XI inhibitor to start enrolling patients in Phase 3 trials.